Related Experiment Video
Updated: Mar 23, 2026
12:30
Production of Nurr-1 Specific Polyclonal Antibodies Free of Cross-reactivity Against Its Close Homologs, Nor1 and Nur77
Published on: August 17, 2015
7.9K
Nurr1-Based Therapies for Parkinson's Disease
Jie Dong1, Song Li1, Jing-Lin Mo1
1The Center for Translational Research on Neurological Diseases, The First Affiliated Hospital, Dalian Medical University, Dalian, China.
CNS Neuroscience & Therapeutics
|March 26, 2016
Summary
Nurr1 (NR4A2) is crucial for dopamine neuron survival and is linked to Parkinson's disease (PD). Activating Nurr1 shows promise for new PD therapies by protecting neurons and enhancing neurotransmission.
Area of Science:
- Neuroscience
- Molecular Biology
- Pharmacology
Background:
- The orphan nuclear receptor Nurr1 (NR4A2) is essential for midbrain dopamine neuron development, differentiation, and survival.
- Defects in Nurr1 function are implicated in the pathogenesis of Parkinson's disease (PD).
Purpose of the Study:
- To review recent preclinical advancements in Nurr1-based therapeutic strategies for Parkinson's disease.
- To discuss the potential of Nurr1 modulators as a novel therapeutic approach for PD.
Main Methods:
- Review of in vitro and in vivo studies on Nurr1-activating compounds and gene therapy.
- Analysis of modulators affecting Nurr1 function, including retinoid X receptor and Wnt/β-catenin pathway.
Main Results:
- Nurr1 activation enhances dopamine neurotransmission and protects dopamine neurons against toxins and neuroinflammation.
- Various modulators can potentially augment the efficacy of Nurr1-based PD therapies.
Conclusions:
- Nurr1-based therapies represent a promising new generation of medication for Parkinson's disease.
- Further preclinical research supports the therapeutic potential of targeting Nurr1 for PD treatment.
Related Concept Videos
01:24Parkinson's Disease: Treatment
1.3K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.3K
01:15Parkinson's Disease: Overview
2.3K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.3K
01:37Neural Regulation
44.6K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
44.6K
01:22Alzheimer's Disease: Treatment
1.2K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.2K
01:11Direct-Acting Cholinergic Agonists: Therapeutic Uses
2.0K
Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren...
2.0K
01:29Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
1.0K
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Phenothiazines, such as prochlorperazine...
1.0K